로딩 중…
StockDiggingStockDigging

Boryung Corporation

003850· KOSPI
₩9,090-0.98%
2026-06-19

Price Chart

Boryung Corporation+9.78%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap779.81B KRW
Revenue1.03T KRW
Net Income105.39B KRW
Total Assets1.40T KRW
Net Assets873.71B KRW
Employees1,646
Value
P/E7.40x
P/B0.89x
PEG0.00x
P/S0.76x
EV/EBITDA9.73x
FCF Yield8.93%
Profitability
ROE12.06%
ROA7.52%
Op. Margin7.20%
Revenue Growth6.15%
Earnings Growth11762.37%
Financial Health
Debt Ratio60.46%
Total Debt199.61B KRW
FCF69.64B KRW
Cash256.18B KRW
Current Ratio2.61x
Net Debt/EBITDA-0.76x
Dividend
Div. Yield1.74%
Div. Growth60.00%
Performance
1Y Return9.78%
1M Return-1.73%
From 52W High-15.83%
1Y MDD-25.84%
Trading
Volume155,628 shares
Foreign Own.6.47%
Per Share
EPS1,229 KRW
BPS10,342 KRW

Company Info

CEO 김정균
Employees 1,646
Founded 1963
HQ 서울 종로구, KR

Boryung, established in 1963 and listed on the securities market in 1988, operates in pharmaceutical manufacturing and sales. The company is expanding its market share in chronic metabolic diseases and oncology with its new drug Kanarb in the professional pharmaceutical sector, achieving results across diverse business divisions. Boryung strives to become a leading healthcare company with high profitability and stable cash generation by maximizing proprietary product capabilities and expanding essential medicine manufacturing infrastructure. Boryung is headquartered in Jongno-gu, Seoul.